## 3 Results
\begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Protein** & **Variant** & **I [\%] 1** & **Predcentage of Activities in the Case of Which Modifications Affect the Value of Parameter A [\%] 2,3** & **Percentage of Activities in the Case of Which Modifications Affect the Value of Parameter A [\%] 3,4** \\ \hline \multirow{4}{*}{\(\alpha_{\text{s1}}\)-CN} & A & 95.70 & 13.04 & 33.33 \\  & B & 95.98 & 12.50 & 33.33 \\  & C & 95.98 & 12.50 & 33.33 \\  & D & 95.48 & 12.50 & 33.33 \\  & A & 94.20 & 26.32 & 20.00 \\  & B & 94.69 & 22.22 & 20.00 \\  & C & 94.20 & 26.32 & 20.00 \\  & D & 95.45 & 26.32 & 20.00 \\  & A1 & 97.61 & 17.86 & 37.50 \\  & A2 & 97.61 & 16.13 & 44.44 \\ \(\beta\)-CN & A3 & 97.61 & 16.13 & 44.44 \\  & B & 97.61 & 16.13 & 44.44 \\  & A & 97.63 & 17.39 & 12.50 \\ \(\kappa\)-CN & B & 97.63 & 13.04 & 12.50 \\  & B2 & 97.63 & 13.04 & 12.50 \\  & C & 97.63 & 13.04 & 12.50 \\ \hline \hline \end{tabular}  
* Identity between a protein sequence containing modifications of amino acid residues and a sequence of the same protein devoid of modifications, computed according to Equation (5). 2 Value of parameter A computed from Equation (1). 3 Complete list of activities of fragments found in proteins and released upon in silico proteolysis is presented in Tables S2–S9 in the Supplementary Materials. 4 Values of parameter A\({}_{\text{E}}\) computed according to Equation (2).  
\end{table} 
Table 2: Percentage of activities in the case of which considering the post-translational modifications affects the values of A and A\({}_{\text{E}}\) parameters. \begin{table}
\begin{tabular}{l l l l l l l l} \hline \hline
**Peptide** & **Protein—Peptide Precursor** & **ACEi 1** & **DPPIVi 2** & **Antivaditative 3** & **DPPIIIi 4** & **\(\alpha\)-Glui 5** & **Others** \\ \hline IA & \(\kappa\)-CN A; B; B2; C & 7562 & 8525 & & & \\ IE & \(\beta\)-CN A1; A2; A3; B & 7827 & & & & \\  & \(\kappa\)-CN A; B; B2; C & \(\alpha_{\text{s1}}\)-CN A; B; C; D; \(\alpha_{\text{s2}}\)-CN A; B; C; & & & & \\ IG & \(\beta\)-CN A1; & 7595 & & & & & \\  & \(\kappa\)-CN B & & & & & & \\  & \(\alpha_{\text{s1}}\)-CN A; B; C; D; & & 8800 & 9497 & 8323 6  \\ IH & \(\beta\)-CN A1; A2; A3; B & & 9079 & 8802 & & & \\ IL & \(\kappa\)-CN A; B; B2; C & 9079 & 8802 & & & \\  & \(\alpha_{\text{s2}}\)-CN A; B; C; D; & & & & & \\ IN & \(\beta\)-CN A1; A2; A3; B; & & 8804 & & & \\  & \(\kappa\)-CN A; B; B2; C & 7581 & 8501 & & & \\ IP & \(\kappa\)-CN A; B; B2; C & 7803 & & & & \\ IPY & \(\kappa\)-CN A; B; C; D & & & & & \\  & \(\alpha_{\text{s1}}\)-CN A; B; C; D; & & & & & \\ IQ & \(\alpha_{\text{s2}}\)-CN A; B; C; D & & & & & \\  & \(\beta\)-CN A1; A2; A3; B; & & & & & \\  & \(\kappa\)-CN A; B; B2; C & & & & & \\  & \(\kappa\)-CN A; B; B2; C & & 3258 & 8806 & 8215 & & 8246 7  \\ PA & \(\kappa\)-CN A; B; B2; C & & & 3179 & & & \\  & \(\alpha_{\text{s1}}\)-CN A; B; C; D & & & & & 9504 & 9694 \\  & \(\beta\)-CN A1; A2; A3; B & & & & & 9505 & \\  & \(\alpha_{\text{s1}}\)-CN A; B; C; D & & & & & 2754  ; 3285  ; 340  \\  & \(\beta\)-CN A1; A2; A3; B & & & & & & 2754  ; 3285  ; 340  \\ PH & \(\beta\)-CN A1; A2; A3; B & & & & & & \\  & \(\kappa\)-CN A; B; B2; C & & & & & \\  & \(\alpha_{\text{s1}}\)-CN A; B; C; D; & & & & & \\  & \(\alpha_{\text{s2}}\)-CN A; B; C; D; & & & & 9504 & 9694 \\  & \(\beta\)-CN A1; A2; A3; B & & & & 9505 & \\ PG & \(\beta\)-CN A1; A2; A3; B & 7625 & 8855 & & & 2754  ; 3285  ; 3460  \\ PH & \(\beta\)-CN A1; A2; A3; B & & & & & & \\  & \(\kappa\)-CN A; B; B2; C & & & & & \\  & \(\alpha_{\text{s1}}\)-CN A; B; C; D; & & & & & \\  & \(\alpha_{\text{s2}}\)-CN A; B; C; D; & & & & 8858 & \\  & \(\beta\)-CN A1; A2; A3; B & & & & & \\ \hline \hline \end{tabular}  
\end{table} 
Table 3: List of bioactive peptides being putative products of digestion of individual casein fractions. Peptide IDs are taken from the BIOPEP-UWM database of bioactive peptides.